To investigate the association of T allele of the C825T polymorphism of the gene encoding the ␤ 3 -subunit of G proteins (GNB3) with blood pressure response to diuretic therapy.
P-158 EFFICACY OF OLMESARTAN MEDOXOMIL (O) AND O/HYDROCHLOROTHIAZIDE (H) IN ACHIEVING BLOOD PRESSURE (BP) CONTROL AND NORMALIZATION IN STAGE 2 SYSTOLIC HYPERTENSION (HTN)
Joseph Izzo, Joel Neutel, Robert Dubiel, Findlay Walker. Dept. of Medicine, State University of New York at Buffalo, Buffalo, NY; Director of Research, Orange County Research Center, Tustin, CA; Medical Affairs, Sankyo Pharma Inc, Parsippany, NJ. The JNC 7 report stresses the importance of reducing systolic BP (SBP) and states that Ն2 agents are usually required to achieve goal BP (Ͻ160 mmHg) in Stage 2 systolic HTN. This study evaluated the efficacy of an open label titration regimen using the angiotensin receptor blocker O alone and in combination with H to achieve goal BP (Ͻ140/90 mmHg) and to normalize BP (Ͻ120/80 mmHg) in Stage 2 systolic HTN. After a placebo run-in, 169 patients (pts) with seated SBP Ն160 and Ͻ200 mmHg and diastolic BP (DBP) Ͻ110 mmHg received O 20 mg/d for 3 wks. Uptitration occurred at 3-wk intervals if BP remained Ն120/80 mmHg according to the schedule: O 40 mg/d, combination with H 12.5 mg/d, then H 25 mg/d. If BP remained Ն120/80 mmHg, pts could enter a 4-wk extension phase, with H increased to 50 mg/d. The primary endpoint was change from baseline in mean trough SBP at 12 wks. Secondary endpoints included BP changes from baseline at the end of each titration period and the percentage of pts achieving BP Ͻ140/90 and Ͻ120/80 mmHg. Mean age was 60 yrs, 46% of pts were male and 84% were non-black; mean baseline BP was 171/95 mmHg. Marked reductions in BP were seen at the end of each titration step (Table; PϽ0.001 compared with baseline for SBP and DBP at all times analyzed). At wk 12, with the highest approved dose (O/H 40/25 mg/d), a mean reduction in SBP of -34.7 mmHg allowed 70% of pts to achieve goal BP Ͻ140/90 mmHg and 15% to achieve normal BP (Ͻ120/80 mmHg). Increasing H to 50 mg/d allowed further reductions in SBP, which led to 78% of pts achieving goal BP and 27% achieving normal BP. In conclusion, O monotherapy is effective in reducing SBP and, combined with H, provides additional BP reduction, resulting in a substantial proportion of pts achieving BP goal and normalization. This study evaluated the metabolic consequences and safety of an open label titration regimen of the angiotensin receptor blocker OLM alone and in combination with HCTZ in Stage 2 systolic HTN. After a placebo run-in, patients (pts) (Nϭ169) with seated SBP Ն160 and Ͻ200 mmHg and diastolic BP (DBP) Ͻ110 mmHg received OLM 20 mg/d for 3 wks. The regimen was modified at 3-wk intervals if BP remained Ն120/80 mmHg: up-titration of OLM to 40 mg/d; addition of HCTZ 12.5 mg/d; and up-titration of HCTZ to 25 mg/d. If pts' BP remained Ն120/80 mmHg, they could enter a 4-wk extension phase, wherein HCTZ was increased to 50 mg/d. The primary endpoint was change from baseline in mean trough SBP after 12 wks of treatment. Mean age was 60 yrs, 46% of pts were male and 84% were non-black; mean baseline BP was 171/95 mmHg. Adverse event (AE) and metabolic data were tabulated for all pts who received Ն1 dose of study medication. Both OLM and HCTZ were well tolerated with a low incidence of AEs across the dosing range. Drug-related AEs occurring in Ն2% of pts included dizziness (OLM 40/HCTZ 12.5, 3.8%; OLM 40/HCTZ 25, 4.9%; OLM 40/HCTZ 50, 5.7%), increased ␥-glutamyl transferase (OLM 40/HCTZ 25, 2.1%), increased serum uric acid (OLM 40/HCTZ 50, 7.6%), increased blood creatinine (OLM 40/HCTZ 25, 2.1%; OLM 40/HCTZ 50, 5.7%), increased blood urea (OLM 40/HCTZ 50, 7.6%) and fatigue (OLM 40/ HCTZ 25, 2.1%). Symptomatic hypotension occurred in 1 pt (0.64%) with OLM 40/HCTZ 12.5 and 1 pt (0.94%) with OLM 40/HCTZ 50. Serum potassium, glucose and uric acid levels remained within normal limits for all OLM/HCTZ combinations ( 
